Aequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 CAD | -33.33% | -33.33% | -60.00% |
1st Jan change | Capi. | |
---|---|---|
-60.00% | 1.45M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- AQS Stock
- News Aequus Pharmaceuticals Inc.
- Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada